ACCESS Newswire
15 Nov 2019, 13:43 GMT+10
HENNIGSDORF, GERMANY / ACCESSWIRE / November 15, 2019 / SphingoTec GmbH ('sphingotec') today announced that latest advancements in the development of its portfolio of novel biomarkers and diagnostic solutions will be showcased at Medica 2019 in Düsseldorf, Germany. To improve the management of critically ill patients in acute care settings through timely diagnostic, sphingotec has started making available novel biomarkers that complement a broad menu of existing standard of care tests on its Nexus IB10 point-of-care platform.
The Nexus IB10 point-of-care technology provides test results on whole blood sample in only 20 minutes and can be flexibly deployed in emergency departments, intensive care units, and any laboratory setting. In addition to the increasing menu of assays for proprietary biomarkers, the platform features a broad menu of 8 rapid tests for acute care settings including parameters such as the Troponin-I, NT-proBNP, and D-Dimer. Following the acquisition of Nexus Dx Inc., San Diego, USA, in 2018 from the Korean manufacturer Samsung, sphingotec markets the Nexus IB10 point-of-care platform through its continuously expanding distribution network.
Visit sphingotec at Medica 2019
sphingotec showcases its Nexus IB10 instrument and test portfolio as well as its proprietary biomarkers for acute care conditions at Medica 2019 and welcomes healthcare professionals as well as distributors and diagnostics and pharmaceutical industry representatives interested in partnering at its booth G52 in hall 3.
References
[1] Takagi et. al. (2019) Circulating dipeptidyl-peptidase 3 and alteration in hemodynamics in cardiogenic shock: Results from the OptimaCC Trial, European Journal of Heart Failure
[2] Deniau et. al. (2019) Circulating dipeptidyl peptidase-3 is a myocardial depressant factor: DPP3 inhibition rapidly and sustainably improves hemodynamics, European Journal of Heart Failure
[3] Siong Chan (2018) Proenkephalin in heart failure
[4] Hollinger et. al. (2018) Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Press Release Kidney in Sepsis and Septic Shock (Kid-SSS) Study
[5] Beunders et. al. (2017) Proenkephalin (PENK) as a novel biomarker for kidney function.
[6] Geven et. al. (2018) Geven 2018 Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in sepsis
[7] Mebazaa et. al. (2018) Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1
(AdrenOSS-1) study
[8] ter Maaten et. al.(2019) Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure
About sphingotec
SphingoTec GmbH ('sphingotec' Hennigsdorf by Berlin, Germany) develops and markets innovative in vitro diagnostic IVD tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec's assay portfolio includes sphingotest(R) bio-ADM(R) the assay for bioactive adrenomedullin, a unique biomarker for real-time assessment of vascular integrity in conditions like sepsis or congestive heart failure, sphingotest(R) penKid(R), the assay for proenkephalin, a unique biomarker for real-time assessment of kidney function and sphingotest(R) DPP3, an assay for Dipeptidyl Peptidase 3, a unique biomarker for signaling pathway disruptions leading to acute organ dysfunction. Along with the Nexus IB10 POC platform by its subsidiary Nexus Dx Inc. (San Diego, CA, USA) acquired from Samsung in 2018, sphingotec markets a standard marker portfolio for acute care. In addition, sphingotec developed a portfolio of novel biomarkers, which predict the risks of obesity, breast cancer and cardiovascular diseases.
Contact:
Ruxandra Lenz
PR and Market Communications Manager
+ 49 3302 20565 34
[email protected]
SOURCE: SphingoTec GmbH
Get a daily dose of Dallas Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Dallas Sun.
More InformationWASHINGTON, D.C.: President Donald Trump has signed an executive order directing the U.S. Commerce Department to ease regulations on...
THE VATICAN - The world is in shock and mourning on Easter Monday as it woke to the news that Pope Francis had died. Having recently...
NEW YORK CITY, New York: A former New York City police sergeant, Michael McMahon, was sentenced this week to 1.5 years in prison. He...
WASHINGTON, D.C.: U.S. Interior Secretary Doug Burgum has ordered a stop to construction of Equinor's Empire Wind project off New York's...
SINGAPORE: Amid rising trade tensions, several Asian nations are stepping up energy purchases from the U.S. in hopes of easing tariff...
WASHINGTON DC - In a bid to combat illegal border crossings, the Trump Administration has enacted an emergency transfer of some 110,000...
BEIJING, China: Apple's grip on China's smartphone market continued to weaken in the first quarter of 2025, with the U.S. tech giant...
WASHINGTON, D.C.: U.S. officials are considering new measures to block China's DeepSeek from acquiring American technology, according...
TOKYO, Japan: Toyota is weighing plans to build the next-generation RAV4 SUV in the United States, according to three people familiar...
WASHINGTON, D.C.: Ford is recalling more than 148,000 vehicles across two safety campaigns, according to a notice issued by the National...
NEW YORK CITY, New York: Archer Aviation has announced plans to start an air-taxi service in New York City, working with United Airlines....
TAIPEI, Taiwan: Taiwan's TSMC reported stronger-than-expected first-quarter earnings on Thursday, driven by booming demand for AI-related...